A<i>Plasmodium falciparum</i>genetic cross reveals the contributions of<i>pfcrt</i>and<i>plasmepsin II/III</i>to piperaquine drug resistance

Abstract Piperaquine (PPQ) is widely used in combination with dihydroartemisinin (DHA) as a first-line treatment against malaria parasites. Multiple genetic drivers of PPQ resistance have been reported, including mutations in thePlasmodium falciparum chloroquine resistance transporter(pfcrt) and increased copies ofplasmepsin II/III(pm2/3). We generated a cross between a Cambodia-derived multi-drug resistant KEL1/PLA1 lineage isolate (KH004) and a drug susceptible parasite isolated in Malawi (Mal31). Mal31 harbors a wild-type (3D7-like) pfcrtallele and a single copy ofpm2/3,while KH004 has a chloroquine-resistant (Dd2-like) pfcrtallele with an additional G367C substitution and four copies ofpm2/3. We recovered 104 unique recombinant progeny and examined a targeted set of progeny representing all possible combinations of variants atpfcrt and pm2/3for detailed analysis of competitive fitness and a range of PPQ susceptibility phenotypes, including PPQ survival assay (PSA), area under the dose-response curve (AUC), and a limited point IC50(LP-IC50). We find that inheritance of the KH004pfcrtallele is required for PPQ resistance, whereas copy number variation inpm2/3further enhances resistance but does not confer resistance in the absence of PPQ-R-associated mutations inpfcrt. Deeper investigation of genotype-phenotype relationships demonstrates that progeny clones from experimental crosses can be used to understand the relative contributionsof pfcrt, pm2/3,and parasite genetic background, to a range of PPQ-related traits and confirm the critical role of the PfCRT G367C substitution in PPQ resistance.Importance Resistance to PPQ used in combination with DHA has emerged in Cambodia and threatens to spread to other malaria-endemic regions. Understanding the causal mutations of drug resistance and their impact on parasite fitness is critical for surveillance and intervention, and can also reveal new avenues to limiting the evolution and spread of drug resistance. An experimental genetic cross is a powerful tool for pinpointing the genetic determinants of key drug resistance and fitness phenotypes and have the distinct advantage of assaying the effects of naturally evolved genetic variation. Our study was significantly strengthened because the full a range of copies of KH004pm2/3was inherited among the progeny clones, allowing us to directly test the roleof pm2/3copy number on resistance-related phenotypes in the context of a uniquepfcrtallele. Our multi-gene model suggests an important role for both loci in the evolution of this ACT resistant parasite lineage..

Medienart:	Preprint

Erscheinungsjahr:	2023
Erschienen:	2023

Enthalten in:	bioRxiv.org - (2023) vom: 20. Sept. Zur Gesamtaufnahme - year:2023

Sprache:	Englisch

Beteiligte Personen:

Kane, John [VerfasserIn] Li, Xue [VerfasserIn] Kumar, Sudhir [VerfasserIn] Button-Simons, Katrina A. [VerfasserIn] Vendrely Brenneman, Katelyn M. [VerfasserIn] Dahlhoff, Haley [VerfasserIn] Sievert, Mackenzie A.C. [VerfasserIn] Checkley, Lisa A. [VerfasserIn] Shoue, Douglas A. [VerfasserIn] Singh, Puspendra P. [VerfasserIn] Abatiyow, Biley A. [VerfasserIn] Haile, Meseret T. [VerfasserIn] Nair, Shalini [VerfasserIn] Reyes, Ann [VerfasserIn] Tripura, Rupam [VerfasserIn] Peto, Tom [VerfasserIn] Lek, Dysoley [VerfasserIn] Kappe, Stefan H.I. [VerfasserIn] Dhorda, Mehul [VerfasserIn] Nkhoma, Standwell C [VerfasserIn] Cheeseman, Ian H. [VerfasserIn] Vaughan, Ashley M. [VerfasserIn] Anderson, Timothy J. C. [VerfasserIn] Ferdig, Michael T. [VerfasserIn]

Links:	Volltext [kostenfrei]

Themen:	570 Biology

doi:	10.1101/2023.06.06.543862

funding:
Förderinstitution / Projekttitel:

PPN (Katalog-ID):	XBI039845370